Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKinsey
Harvard Business School
Moodys
Express Scripts

Last Updated: August 8, 2022

Investigational Drug Information for Iniparib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Iniparib?

Iniparib is an investigational drug.

There have been 21 clinical trials for Iniparib. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2009.

The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Carcinoma, Ovarian Epithelial. The leading clinical trial sponsors are Sanofi, Cantargia AB, and BiPar Sciences.

Recent Clinical Trials for Iniparib
TitleSponsorPhase
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.Spanish Breast Cancer Research GroupPhase 1/Phase 2
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.Cantargia ABPhase 1/Phase 2
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical TrialSanofiPhase 3

See all Iniparib clinical trials

Clinical Trial Summary for Iniparib

Top disease conditions for Iniparib
Top clinical trial sponsors for Iniparib

See all Iniparib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKinsey
Harvard Business School
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.